The #1 Biotech Stock to Own Right Now

That's the name of the most popular drug doctors prescribed last year to fight leukemia.  Dear Reader, Cytarbine. That's the name of the [most popular drug]( doctors prescribed last year to fight leukemia. Problem is, Cytarbine is a "chemical drug" that was patented almost 60 years ago. Chemical drugs are like nuclear weapons. Drop them inside your body and everything gets destroyed. It's why people say, "the chemo will get you before the cancer does." It gets even worse... 75% of all cancer drugs sold by Big Pharma are old chemical drugs like Cytarbine. Well guess what? On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of treatment that can "Cut & Paste" any disease from your body. It's like this tiny biotech invented the iPhone while Big Pharma is still selling flip phones. And our research proves that [anyone who gets in today could turn every $1,000 into $1.54 million (or more)!]( The Big Pharma companies that have the most to lose from this new treatment are Bristol Meyers, Pfizer, Sanofi, Novartis and Teva. Sanofi has their own new drug on the market. Pfizer last month bought Array Biopharma, which we recommended. That leaves Novartis, Teva and Bristol Meyers. We think Bristol Meyers is the most likely buyer because their new leukemia drug recently flunked out of FDA trials. A deal could happen any day. A takeover of the company could hand investors [gains of up to $31,250 in the next 90 days...]( But we would be ok if there wasn't a deal. That's because Investor's Business Daily estimates this is a $75 billion market. Yet right now, its stock price is just a tiny fraction of that size. [CLICK HERE to see how you can profit from this rare opportunity]( Sincerely, Josh K. Editor-in-Chief, Behind the Markets If you are you having trouble receiving your FutureOfTrading subscription, you can ensure its arrival in your mailbox by [whitelisting FutureOfTrading and fot@FutureOfTrading.org.]( FutureOfTrading (collectively, the “Company” or “we” used herein) bears no responsibility or control over the content of the advertisement and/or the product or service offered. This email is a paid advertisement. It is for a product or service that is not offered, recommended or endorsed by FutureOfTrading and neither the company nor its affiliates bear responsibility or control over the content of the advertisement and the product or service offered. There is a very high degree of risk involved in trading. Past results are not indicative of future returns. FutureOfTrading, all individuals and companies affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as advice. Information for any trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. By reading, downloading or otherwise consuming this content your information may be shared with our educational partners. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of FutureOfTrading may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.  Your subscriber Id is: 39357a76f6d08b16239fd2ffa65e9c6f Proudly brought to you by: FutureOfTrading of 3rd Fl, N&S Tower, 4 Selsdon Way, London, E14 9GL, UK In order to unsubscribe from this mailing list, please click [here](